These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32188047)

  • 1. Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.
    Wahl RU; Leijs M; Araujo A; Rübben A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
    Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of immunotherapy and surgery for stage IV melanoma.
    Molina G; Kasumova GG; Qadan M; Boland GM
    Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
    Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
    J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
    Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
    Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas.
    Hoyek S; Kourie HR; Labaki C; Antoun J
    Immunotherapy; 2020 Nov; 12(16):1149-1152. PubMed ID: 33076742
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
    Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
    Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the benefit of immunotherapy for stage III melanoma.
    Desai AD; Ibrahim SJ; Samie FH
    J Am Acad Dermatol; 2024 Sep; 91(3):521-522. PubMed ID: 38685406
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.
    Bjursten S; Zhao Z; Al Remawi H; Studahl M; Pandita A; Simrén J; Zetterberg H; Lundell AC; Rudin A; Ny L; Levin M
    EBioMedicine; 2024 Feb; 100():104955. PubMed ID: 38171113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
    Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
    Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of Immunotherapy in Melanoma.
    Onitilo AA; Wittig JA
    Surg Clin North Am; 2020 Feb; 100(1):161-173. PubMed ID: 31753110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
    Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
    Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
    Mao R; Yang F; Zhang T; Li J
    Front Immunol; 2021; 12():756282. PubMed ID: 35003069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.
    Carey AE; Weeraratna AT
    Pharmacol Ther; 2024 Oct; 262():108698. PubMed ID: 39098769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.